GURUFOCUS.COM » STOCK LIST » USA » NYSE » Bristol-Myers Squibb Co (NYSE:BMY) » Definitions » Piotroski F-Score
Switch to:

Bristol-Myers Squibb Co Piotroski F-Score

: 8 (As of Today)
View and export this data going back to 1952. Start your Free Trial

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bristol-Myers Squibb Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Bristol-Myers Squibb Co's Piotroski F-Score or its related term are showing as below:

BMY' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 9
Current: 8

During the past 13 years, the highest Piotroski F-Score of Bristol-Myers Squibb Co was 9. The lowest was 2. And the median was 6.


Bristol-Myers Squibb Co Piotroski F-Score Historical Data

The historical data trend for Bristol-Myers Squibb Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bristol-Myers Squibb Co Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 9.00 4.00 4.00 8.00

Bristol-Myers Squibb Co Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 5.00 8.00 8.00 8.00

Competitive Comparison

For the Drug Manufacturers - General subindustry, Bristol-Myers Squibb Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Bristol-Myers Squibb Co Piotroski F-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Bristol-Myers Squibb Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Bristol-Myers Squibb Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun22) TTM:Last Year (Jun21) TTM:
Net Income was 1546 + 2372 + 1278 + 1421 = $6,617 Mil.
Cash Flow from Operations was 5266 + 4057 + 3812 + 2261 = $15,396 Mil.
Revenue was 11624 + 11985 + 11648 + 11887 = $47,144 Mil.
Gross Profit was 9333 + 9629 + 9177 + 9167 = $37,306 Mil.
Average Total Assets from the begining of this year (Jun21)
to the end of this year (Jun22) was
(110797 + 110893 + 109314 + 103034 + 100357) / 5 = $106879 Mil.
Total Assets at the begining of this year (Jun21) was $110,797 Mil.
Long-Term Debt & Capital Lease Obligation was $37,922 Mil.
Total Current Assets was $30,186 Mil.
Total Current Liabilities was $20,915 Mil.
Net Income was 1872 + -10027 + 2021 + 1055 = $-5,079 Mil.

Revenue was 10540 + 11068 + 11073 + 11703 = $44,384 Mil.
Gross Profit was 8038 + 8158 + 8232 + 9251 = $33,679 Mil.
Average Total Assets from the begining of last year (Jun20)
to the end of last year (Jun21) was
(128076 + 125536 + 118481 + 112435 + 110797) / 5 = $119065 Mil.
Total Assets at the begining of last year (Jun20) was $128,076 Mil.
Long-Term Debt & Capital Lease Obligation was $43,465 Mil.
Total Current Assets was $29,161 Mil.
Total Current Liabilities was $18,991 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bristol-Myers Squibb Co's current Net Income (TTM) was 6,617. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Bristol-Myers Squibb Co's current Cash Flow from Operations (TTM) was 15,396. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun21)
=6617/110797
=0.05972183

ROA (Last Year)=Net Income/Total Assets (Jun20)
=-5079/128076
=-0.03965614

Bristol-Myers Squibb Co's return on assets of this year was 0.05972183. Bristol-Myers Squibb Co's return on assets of last year was -0.03965614. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Bristol-Myers Squibb Co's current Net Income (TTM) was 6,617. Bristol-Myers Squibb Co's current Cash Flow from Operations (TTM) was 15,396. ==> 15,396 > 6,617 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun21 to Jun22
=37922/106879
=0.35481245

Gearing (Last Year: Jun21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun20 to Jun21
=43465/119065
=0.3650527

Bristol-Myers Squibb Co's gearing of this year was 0.35481245. Bristol-Myers Squibb Co's gearing of last year was 0.3650527. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun22)=Total Current Assets/Total Current Liabilities
=30186/20915
=1.44327038

Current Ratio (Last Year: Jun21)=Total Current Assets/Total Current Liabilities
=29161/18991
=1.53551682

Bristol-Myers Squibb Co's current ratio of this year was 1.44327038. Bristol-Myers Squibb Co's current ratio of last year was 1.53551682. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Bristol-Myers Squibb Co's number of shares in issue this year was 2149. Bristol-Myers Squibb Co's number of shares in issue last year was 2252. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=37306/47144
=0.79132021

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=33679/44384
=0.75880948

Bristol-Myers Squibb Co's gross margin of this year was 0.79132021. Bristol-Myers Squibb Co's gross margin of last year was 0.75880948. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun21)
=47144/110797
=0.42549889

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun20)
=44384/128076
=0.34654424

Bristol-Myers Squibb Co's asset turnover of this year was 0.42549889. Bristol-Myers Squibb Co's asset turnover of last year was 0.34654424. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Bristol-Myers Squibb Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Bristol-Myers Squibb Co  (NYSE:BMY) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Bristol-Myers Squibb Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Bristol-Myers Squibb Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Bristol-Myers Squibb Co Business Description

Bristol-Myers Squibb Co logo
Address
430 East 29th Street, 14th Floor, New York, NY, USA, 10016
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, oncology, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Executives
Greenlees Sharon officer: SVP & Controller BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Shanahan Karin officer: EVP, Glob. Prod. Dev. & Supply BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Meyers Gregory Scott officer: EVP, Chief Digital & Tech Off. BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Weese Michelle officer: EVP, Corporate Affairs BRISTOL MYERS SQUIBB ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Hidalgo Medina Manuel director BRISTOL MYERS SQUIBB 430 E. 29TH STREET, 14TH FLOOR NEW YORK NY 10016
Rice Derica W director 1000 NICOLLET MALL TPS-3155 MINNEAPOLIS MN 55403
Price Paula A director ONE CVS DRIVE WOONSOCKET RI 02895
Mily Elizabeth officer: EVP, Strategy & BD BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVENCE LINE ROAD PRINCETON NJ 08540
Metcalfe Kathryn officer: EVP, Corporate Affairs BRISTOL-MYERS SQUIBB COMPANY ROUTE 206 & PROVINCE LINE ROAD PRINCETON NJ 08543
Vessey Rupert officer: Pres., Research & Early Dev. C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Elkins David V officer: EVP, Chief Financial Officer C/O BECTON, DICKINSON AND COMPANY 1 BECTON DRIVE FRANKLIN LAKES NJ 07417
Bonney Michael W director 65 HAYDEN AVE LEXINGTON MA 02421
Yale Phyllis R director
Ahmed Nadim officer: President, Hematology C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901
Haller Julia A director C/O CELGENE CORPORATION 86 MORRIS AVENUE SUMMIT NJ 07901

Bristol-Myers Squibb Co Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)